REG - RTW Biotech Opp. - Baroness Blackwood Appointed as Independent NED

RTW Biotech OpportunitiesAnnouncement

11/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240711:nRSK9505Va&default-theme=true

RNS Number : 9505V  RTW Biotech Opportunities Ltd  11 July 2024

LEI: 549300Q7EXQQH6KF7Z84

11 July 2024

RTW Biotech Opportunities Ltd

Baroness Nicola Blackwood Appointed as Independent Non-Executive Director

 

RTW Biotech Opportunities Ltd (the "Company"), a London Stock Exchange-listed
investment company focused on identifying transformative assets with high
growth potential across the life sciences sector, announces that Baroness
Nicola Blackwood has been appointed to the Company's Board of Directors as an
independent, Non-Executive Director, effective the 11th of July 2024.

 

Nicola is a leader in science and entrepreneurship. She is a member of the
House of Lords, and Chair of Genomics England and Oxford University
Innovation. Since 2023, she has been a Supervisory Board member of the
biotechnology company, BioNTech. Nicola served as Minister for Innovation in
the Department for Health and Social Care under two Prime Ministers where she
led on Lifesciences, NHS Data and Digital Transformation, and Global Health
Security. She was the first female MP for Oxford and was elected by MPs of all
parties to Chair the Commons Science and Tech Committee. She remains one of
the youngest committee chairs in British history and the only woman to have
chaired the Commons Science & Tech Committee.

 

Bill Scott, Chair of the Nomination and Remuneration Committee, who led the
appointment process said, "We are delighted to welcome Baroness Blackwood to
the board of RTW Biotech Opportunities Ltd.  Nicola brings with her a
remarkable blend of skills and experience, having operated at the highest
levels of government and leadership roles in the facilitation of fundamental
research and strategic commercialisation of promising innovation in life
sciences both in the UK and overseas.  We look forward to working with her to
take RTW Biotech Opportunities to the next level as the leading investment
fund in its sector on the London market and in further advancing the UK and
European biotech ecosystem."

William Simpson, Chair of the Board, said, "Nicola's involvement in science
and technology, within and outside of government, provides us with significant
additional knowledge from which we all will benefit.  The performance of the
Company since inception has been excellent and Nicola's contribution will help
us further develop our mission to harness innovation in biotech to the
advantage of patients and shareholders."

Nicola Blackwood said, "I am delighted to be joining the RTW Biotech
Opportunities Ltd Board. Life sciences and innovation will be central in
tackling many of the global challenges we face today. I look forward to
engaging with the RTW team and playing a part in powering innovations from
breakthrough to high-growth companies."

 

No further details are required to be disclosed under LR 9.6.13

 

For Further Information

 RTW Investments, LP                                      +44 20 7959 6361
 Woody Stileman, Managing Director, Business Development  biotechopportunities@rtwfunds.com (mailto:biotechopportunities@rtwfunds.com)

 Krisha McCune, Director, Investor Relations

 Buchanan (PR & Communications Adviser)                   +44 20 7466 5107
 Charles Ryland
 Henry Wilson
 George Beale

 Deutsche Numis (Joint Corporate Broker)                  +44 20 7260 1000
 Freddie Barnfield
 Nathan Brown
 Euan Brown

 BofA Securities (Joint Corporate Broker)                 +44 20 7628 1000
 Edward Peel
 Alex Penney

 Cadarn Capital (Distribution & IR Partner)               +44 73 6888 3211
 David Harris

 Elysium Fund Management Limited                          +44 14 8181 0100

 Joanna Duquemin Nicolle, Chief Executive Officer

 Sadie Morrison, Managing Director

 Morgan Stanley Fund Services USA LLC                     +1 914 225 8885

 

About Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund
focused on identifying transformative assets with high growth potential across
the biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/)  for more
information.

 

***********

The information in this announcement may include forward-looking statements,
which are based on the current expectations and projections about future
events, and in certain cases can be identified by the use of terms such as
"may", "will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives thereon) or other
variations thereon or comparable terminology. These forward-looking
statements, as well as those included in any related materials, are subject to
risks, uncertainties and assumptions about the Company and/or its underlying
investments, including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use of financing
proceeds and future capital expenditures and acquisitions. In light of these
risks, uncertainties and assumptions, the events in the forward-looking
statements may not occur.

The information contained in this announcement is given at the date of its
publication (unless otherwise marked). No reliance may be placed for any
purpose whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or fairness.

***********

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFBLLFZDLBBBX